Modulation of Human Dendritic Cell Development by Adjuvants and Vaccines

$555,535U19FY2015AINIH

Rockefeller University, New York NY

Investigators

Linked publications & trials

Paper 39437779 Paper 39316623 Paper 39268652 Paper 39023559 Paper 37715951 Paper 37429907 Paper 37368240 Paper 37202422 Paper 37084725 Paper 36752204 Paper 36701425 Paper 36653360 Paper 36565698 Paper 36538032 Paper 36473496 Paper 36409896 Paper 36032981 Paper 35982682 Paper 35976993 Paper 35818364 Paper 35797920 Paper 35796685 Paper 35781671 Paper 35776090 Paper 35664993 Paper 35447027 Paper 35336960 Paper 35235456 Paper 35132412 Paper 35075455 Paper 35043109 Paper 35040666 Paper 35030645 Paper 35025672 Paper 34648371 Paper 34619745 Paper 34547765 Paper 34521836 Paper 34464594 Paper 34413139 Paper 34331873 Paper 34319348 Paper 34265243 Paper 34234131 Paper 34126625 Paper 34083490 Paper 34075373 Paper 33914041 Paper 33831141 Paper 33767397 Paper 33758864 Paper 33758856 Paper 33658717 Paper 33567448 Paper 33533915 Paper 33482248 Paper 33461210 Paper 33442697 Paper 33382968 Paper 33377023 Paper 33357464 Paper 33330867 Paper 33288661 Paper 33288645 Paper 33211088 Paper 33169014 Paper 33112236 Paper 33093202 Paper 32995782 Paper 32995758 Paper 32972996 Paper 32972995 Paper 32941787 Paper 32938700 Paper 32935095 Paper 32839788 Paper 32785687 Paper 32782358 Paper 32766586 Paper 32702737 Paper 32692348 Paper 32676593 Paper 32645326 Paper 32577658 Paper 32577645 Paper 32555388 Paper 32511384 Paper 32504577 Paper 32416070 Paper 32402275 Paper 32285199 Paper 32209664 Paper 32025908 Paper 32014647 Paper 31413072 Paper 31270247 Paper 31121434 Paper 30403995 Paper 30222771 Paper 30143481

Abstract

Most successful vaccines have been developed empirically, with little or no immunological insights. Continued existence of this gap has been a major barrier to the successful development of rationally designed vaccines. Due to their capacity to elicit and regulate immune responses, dendritic cells (DCs) are essential to any effort for vaccine development. The study of conventional DCs (cDCs) from humans has focused on cells in blood, which comprise BDCA-1+ myeloid DCs, BDCA-2+ plasmacytoid DCs, and a small subset of BDCA-3 high, myeloid DCs. The heterogeneity among DCs is of interest because of the specialized functional properties of each DC subset. But a comprehensive model that describes cDC genesis and the origins of cDC functional diversity in humans is lacking. To address this important gap in our understanding of this essential cell type, we propose to uncover the origin of human cDCs and to determine how adjuvants or vaccines alter cDC development. The hypothesis to be tested is that human cDC development, subset distribution, and their state of activation is altered by administration of adjuvants or vaccines. We will first elucidate the origin of cDCs in humans by identifying the human pre-DCs and by determining whether there are one or two lineages of pre-DCs corresponding to the two major myeloid cDC subsets (aim 1). Second, using clinical samples from individuals treated with increasing doses of Flt3L, we will determine if FItSL administration might Improve vaccine efficacy by mobilizing cDCs and their progenitors (aim 2). Lastly, we will define if adjuvants (I.e. TLR3 and TLR4 agonists) or vaccines (I.e. FDA-approved vaccines as well as a DC-targeted vaccine) administration impacts on cDC development in humans (aim 3). Taken together, these experiments should provide a comprehensive model of cDC development both in steady state and inflammatory condition. Understanding these processes will provide important insights into vaccine design.

View original record on NIH RePORTER →